A phase II trial of 4-demethoxydaunorubicin in refractory epithelial ovarian cancer

Gynecol Oncol. 1986 May;24(1):23-6. doi: 10.1016/0090-8258(86)90004-1.

Abstract

Sixteen evaluable patients with refractory epithelial ovarian cancer were treated with oral 4-demethoxydaunorubicin. The drug was given in divided doses over 5 days and dosage was repeated every 3 weeks. There were no objective remissions. Three patients had stabilized disease of 5 to 7 months duration. Although well tolerated, this anthracycline has modest effectiveness against previously treated ovarian cancer.

MeSH terms

  • Adult
  • Aged
  • Daunorubicin / analogs & derivatives*
  • Daunorubicin / therapeutic use
  • Dose-Response Relationship, Drug
  • Drug Evaluation
  • Female
  • Humans
  • Idarubicin
  • Leukocyte Count / drug effects
  • Middle Aged
  • Ovarian Neoplasms / drug therapy*

Substances

  • Idarubicin
  • Daunorubicin